Natera Announces Pricing of Follow-On Offering

About this update from Natera, Inc.

[{"type":"text","content":"AUSTIN, Texas, Nov. 15, 2022 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the pricing of its underwritten public offering of 11,430,000 shares of its common stock at a price to the public of $35.00 per share. Closing of the offering is expected to occur on November 18, 2022, subject to customary closing conditions. In addition, Natera has granted the underwriters a 30-day option to purchase up to an additional 1,714,500 shares of its common stock at the public offering price less the underwriting discounts and commissions.\n\n \n \n \n \n \n \n\n \nMorgan Stanley, Cowen and SVB Securities are acting as joint book-running managers for the offering. Baird is acting as lead manager for the offering. BTIG, Canaccord Genuity, Craig-Hallum and Stephens Inc. are acting as co-managers for the offering.\nThe securities described above are being offered pursuant to an automatically effective shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission on November 15, 2022. The offering is being made only by means of an effective registration statement, including a preliminary prospectus and, when available, final prospectus, copies of which may be obtained by contacting Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by email at [email protected] or by telephone at (833) 297-2926; or SVB Securities LLC Attention: Syndicate Department 53 State Street, 40th Floor Boston, MA 02109 by telephone at 1-800-808-7525 ex. 6132 or by email at [email protected].\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\nAbout NateraNatera™ is a global leader in cell-free DNA testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health an...

More updates from Natera, Inc.